Added to YB: 2024-06-26
Pitch date: 2024-06-20
EIGRQ [bullish]
Eiger BioPharmaceuticals, Inc.
-15.84%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
On September 30, 2024, Eiger BioPharmaceuticals, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy.
Market Cap
$12.6M
Pitch Price
$10.10
Price Target
18.44 (+117%)
Dividend
N/A
EV/EBITDA
-0.39
P/E
-0.17
EV/Sales
1.77
Sector
Biotechnology
Category
special_situation
Show full summary:
Eiger BioPharmaceuticals: Potential Upside in Restructuring and Asset Monetization
EIGRQ: $30.11/sh cash + Lonafarnib value. $80.8M from Zokinvy/Avexitide sale. Low burn rate in Ch11. Propel Bio sees value in Lonafarnib for HDV. $18.44 PT, 45% upside. Max position 67.5K shares (4.5% of float). $9M paid to Merck from Zokinvy. Potential +$8/sh if burn excludes creditor claims.
Read full article (1 min)